Publications by authors named "Akhtar Ashfaq"

Claim this Profile
E
Effect of race, gender and age on intrinsic diurnal variation of serum calcifediol: Insights into vitamin D toxicity.
Charles W Bishop, John Choe, Stephen A Strugnell, Samir Tabash, Akhtar Ashfaq

J Steroid Biochem Mol Biol· February 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Managing Dysregulated Vitamin D Metabolism in CKD: Time to Update Conventional Wisdom?
Charles W Bishop, Akhtar Ashfaq, John Choe, Keith C Norris, Stuart M Sprague

Kidney360· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjunctive Active Vitamin D Decreases Kidney Function during Treatment of Secondary Hyperparathyroidism with Extended-Release Calcifediol in Non-Dialysis Chronic Kidney Disease in a Randomized Trial.
Akhtar Ashfaq, John Choe, Stephen A Strugnell, Nilay Patel, Stuart M Sprague, Akhtar Ashfaq

Am J Nephrol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-dose extended-release calcifediol successfully treated advanced secondary hyperparathyroidism in an end-stage kidney disease patient: a case report.
Akhtar Ashfaq, John Choe, Samir Tabash, Stephen A Strugnell, Laura L Johnson

BMC Nephrol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extended-Release Calcifediol Normalized 1,25-Dihydroxyvitamin D and Prevented Progression of Secondary Hyperparathyroidism in Hemodialysis Patients in a Pilot Randomized Clinical Trial.
Charles W Bishop, Akhtar Ashfaq, John Choe, Stephen A Strugnell, Laura L Johnson

Am J Nephrol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extended-Release Calcifediol: A Data Journey from Phase 3 Studies to Real-World Evidence Highlights the Importance of Early Treatment of Secondary Hyperparathyroidism.
Domenico Merante, Henrik Schou, Isabelle Morin, Marius Manu, Akhtar Ashfaq

Nephron· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sustained Reduction of Elevated Intact Parathyroid Hormone Concentrations with Extended-Release Calcifediol Slows Chronic Kidney Disease Progression in Secondary Hyperparathyroidism Patients.
Charles W Bishop, Akhtar Ashfaq, Stephen A Strugnell, John Choe, Nilay Patel

Am J Nephrol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Therapies for Secondary Hyperparathyroidism Associated with Vitamin D Insufficiency in Chronic Kidney Disease.
Stephen A Strugnell, Philipp Csomor, Akhtar Ashfaq, Charles W Bishop

Kidney Dis (Basel)· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
REsCue trial: Randomized controlled clinical trial with extended-release calcifediol in symptomatic COVID-19 outpatients.
Charles W Bishop, Akhtar Ashfaq, Joel Z Melnick, Enrique Vazquez-Escarpanter, Jonathan A Fialkow

Nutrition· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors in nephrologists' decision to treat pre-dialysis CKD patients with vitamin D insufficiency and SHPT: A discrete choice experiment.
Anand C Reddy, Andy Nguyen, November H McGarvey, Matthew D Gitlin, Charles W Bishop, Akhtar Ashfaq

PLoS One· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world assessment: effectiveness and safety of extended-release calcifediol and other vitamin D therapies for secondary hyperparathyroidism in CKD patients.
Michael J Germain, Subir K Paul, George Fadda, Varshasb Broumand, Andy Nguyen, Akhtar Ashfaq

BMC Nephrol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extended-Release Calcifediol Effectively Raises Serum Total 25-Hydroxyvitamin D Even in Overweight Nondialysis Chronic Kidney Disease Patients with Secondary Hyperparathyroidism.
Charles W Bishop, Stephen A Strugnell, Philipp Csomor, Edelgard Kaiser, Akhtar Ashfaq

Am J Nephrol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Assessment: Clinical Effectiveness and Safety of Extended-Release Calcifediol.
George Fadda, Michael J Germain, Varshasb Broumand, Andy Nguyen, November McGarvey, Akhtar Ashfaq

Am J Nephrol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Testing Patterns for CKD-MBD Abnormalities in a Sample US Population.
James B Wetmore, Yuanyuan Ji, Akhtar Ashfaq, David T Gilbertson, Nicholas S Roetker

Kidney Int Rep· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adherence to Kidney Disease: Improving Global Outcomes Mineral and Bone Guidelines for Monitoring Biochemical Parameters.
Nicholas S Roetker, Yi Peng, Akhtar Ashfaq, David T Gilbertson, James B Wetmore

Am J Nephrol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rationale for Raising Current Clinical Practice Guideline Target for Serum 25-Hydroxyvitamin D in Chronic Kidney Disease.
Stephen A Strugnell, Stuart M Sprague, Akhtar Ashfaq, Martin Petkovich, Charles W Bishop

Am J Nephrol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The cost-effectiveness of extended-release calcifediol versus paricalcitol for the treatment of secondary hyperparathyroidism in stage 3-4 CKD.
Kamyar Kalantar-Zadeh, Christopher S Hollenbeak, Roy Arguello, Sophie Snyder, Akhtar Ashfaq

J Med Econ· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-Effectiveness and Estimated Health Benefits of Treating Patients with Vitamin D in Pre-Dialysis.
Sophie Snyder, Christopher S Hollenbeak, Kamyar Kalantar-Zadeh, Matthew Gitlin, Akhtar Ashfaq

Forum Health Econ Policy· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epidemiology and health outcomes associated with hyperkalemia in a primary care setting in England.
Laura Horne, Akhtar Ashfaq, Sharon MacLachlan, Marvin Sinsakul, Lei Qin

BMC Nephrol· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Excess Deaths Attributable to Influenza-Like Illness in the ESRD Population.
David T Gilbertson, Kenneth J Rothman, Glenn M Chertow, Brian D Bradbury, M Alan Brookhart, Akhtar Ashfaq

J Am Soc Nephrol· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Leadership in the Industry Arena: Nephrologists in Nonclinical Leadership Roles.
Akhtar Ashfaq

Adv Chronic Kidney Dis· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epoetin Alfa and Outcomes in Dialysis amid Regulatory and Payment Reform.
Glenn M Chertow, Jiannong Liu, Keri L Monda, David T Gilbertson, M Alan Brookhart, Akhtar Ashfaq

J Am Soc Nephrol· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time savings of weekly versus three-times-per-week administration of erythropoiesis stimulating agents in United States dialysis patients.
J Mark Stephens, Larry C Emerson, Leslie A Spry, John P Caloyeras, Ernest R Anderson, Akhtar Ashfaq

Curr Med Res Opin· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TSAT is a better predictor than ferritin of hemoglobin response to Epoetin alfa in US dialysis patients.
Adam E Gaweda, Premila Bhat, Gregory A Maglinte, Chun-Lan Chang, Jerrold Hill, Akhtar Ashfaq

Hemodial Int· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outpatient red blood cell transfusion payments among patients on chronic dialysis.
Matthew Gitlin, J Andrew Lee, David M Spiegel, Jeffrey L Carson, Xue Song, Akhtar Ashfaq

BMC Nephrol· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis